Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland flag Poland · Delayed Price · Currency is PLN
34.90
+1.20 (3.56%)
Jul 1, 2025, 4:46 PM CET

WSE:CTX Income Statement

Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
13.9315.8313.29.163.99-
Revenue Growth (YoY)
-13.84%19.88%44.15%129.75%--
Cost of Revenue
4.585.236.32.090.74-
Gross Profit
9.3410.66.97.073.25-
Selling, General & Admin
11.7411.4616.1424.0730.689.89
Research & Development
42.9243.970.8944.1623.1223.57
Other Operating Expenses
-5.35-5.79-7.11-22.79-17.71-21.24
Operating Expenses
49.3149.5679.9245.4436.0912.22
Operating Income
-39.96-38.97-73.02-38.36-32.84-12.22
Interest Expense
-0.43-0.39-0.27-0.32-0.4-0.39
Interest & Investment Income
0.91.043.083.13--
Currency Exchange Gain (Loss)
-0.19-0.07-0.27-0.08-0.06-0.09
Other Non Operating Income (Expenses)
-0.03-0.05-0.05-0.26-0.41-
EBT Excluding Unusual Items
-39.71-38.43-70.53-35.89-33.7-12.69
Asset Writedown
----1.13-
Pretax Income
-39.71-38.43-70.53-35.89-32.57-12.69
Income Tax Expense
--0.06---
Net Income
-39.71-38.43-70.58-35.89-32.57-12.69
Net Income to Common
-39.71-38.43-70.58-35.89-32.57-12.69
Shares Outstanding (Basic)
555444
Shares Outstanding (Diluted)
555444
Shares Change (YoY)
2.46%0.30%11.46%0.97%14.99%-
EPS (Basic)
-8.15-8.25-15.19-8.61-7.89-3.54
EPS (Diluted)
-8.15-8.25-15.19-8.61-7.89-3.54
Free Cash Flow
0.93-32.3-55.21-23.84-33.59-0.81
Free Cash Flow Per Share
0.19-6.93-11.88-5.72-8.14-0.23
Gross Margin
67.10%66.95%52.28%77.21%81.41%-
Operating Margin
-286.95%-246.24%-553.11%-418.91%-823.88%-
Profit Margin
-285.11%-242.82%-534.69%-391.94%-817.16%-
Free Cash Flow Margin
6.67%-204.12%-418.22%-260.32%-842.60%-
EBITDA
-34.8-33.91-67.58-31.27-25.49-5.61
EBITDA Margin
-249.86%-214.27%----
D&A For EBITDA
5.175.065.447.097.366.6
EBIT
-39.96-38.97-73.02-38.36-32.84-12.22
EBIT Margin
-286.95%-246.24%----
Updated Nov 8, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.